Sumatriptan: A decade of use and experience in the treatment of migraine

Expert Review of Neurotherapeutics

Volumn 4, Issue 2, 2004, Pages 199-209

  Sheftell, Fred D ^a,b   Bigal, Marcelo E ^a,c   Tepper, Stewart J ^a,d   Rapoport, Alan M ^a,e  

^a NEW ENGLAND CENTER FOR HEADACHE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Columbia University ^*  (United States)

Author keywords

Migraine; Sumtriptan; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; CALCITONIN GENE RELATED PEPTIDE; N METHYL DEXTRO ASPARTIC ACID; NITRIC OXIDE; OPIATE; RECEPTOR; SEROTONIN; SEROTONIN AGONIST; SOMATOSTATIN; SUMATRIPTAN; SUMATRIPTAN SUCCINATE;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIPOPHILICITY; MENSTRUATION; MIGRAINE; QUALITY OF LIFE; REVIEW; SUPPOSITORY; TABLET; TASTE DISORDER;

CLINICAL TRIALS; HUMANS; MIGRAINE DISORDERS; SUMATRIPTAN;

EID: 1542314346     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.2.199     Document Type: Review

References (65)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and Burden of migraine in the United States: data from the American Migraine Study II. Headache 41, 646-657 (2001).
2. Scher AI, Stewart WF, Lipton RB Migraine and headache: a meta-analytic approach. In: Epidemiology of Pain. Crombie IK (Ed.). IASP Press, WA, USA, 159-170 (1999).
3. Goadsby PJ. Pathophysiology of headache. In: Wolff's Headache and Other Head Pain. Seventh Edition. Silberstein SD, Lipton RB, Dalessio DJ (Eds). Oxford University Press, NY, USA, 57-72 (2001).
4. Moskovitz MA. Basic mechanisms in vascular headache. Neurol. Clin. 8, 801-815 (1990).
5. Blumenthal HJ, Rapoport AM. The clinical spectrum of migraine. In: The Medical Clinics of North America. Volume 85. Mathew NT (Ed.). WB Saunders, PA, USA 897-909 (2001).
6. Humphrey PP. How it started. Cephalalgia 21(Suppl. 1), 2-5 (2001). Historical overview of the development of sumatriptan.
7. Tfelt-Hansen P, Saxena PR, Dahlof C et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 123(Pt 1), 9-18 (2000).
8. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 17 358(9294), 1668-1675 (2001).
9. Tepper SJ, Rapoport AM. The triptans: a summary. CNS Drugs 12, 403-417 (1999).
10. Poondru S, Devaraj R, Boinpally RR, Yamasani MR. Chronopharmacokinetics of sumatriptan in healthy human subjects. J. Pharm. Pharmacol. 52(9), 1085-1090 (2000).
11. Fowler PA, Lacey LF, Thomas M et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur. Neurol. 31, 291-294 (1991).
12. 1-like agonist GR43175 in healthy volunteers.
13. Fuseau E, Petricoul O, Moore KH, Barrow A, Ibbotson T. Clinical pharmacokinetics of intranasal sumatriptan. Clin. Pharmacokinet. 41(11), 801-811 (2002).
14. Warner PE, Brouwer KLR, Hussey EK et al. Sumatriptan absorption from different regions of the human gastrointestinal tract. Pharm. Res. 12, 138-143 (1995).
15. Dixon CM, Saynor DA, Andrew PD et al. Disposition of sumatriptan in laboratory animals and humans. Drug Metabol. Disp. 21, 761-769 (1993).
16. Mansbach H. Sumatriptan: looking back and looking forward. In: The triptans: Novel Drugs For Migraine. Humphrey P, Ferrari M, Olesen J (Eds). Oxford University Press, NY, USA 183-189 (2001). Critical evaluation of sumatriptan.
17. Busch MA, Plachetka JR, Donn KH. Evaluation of the pharmacokinetics and safety of ascending single oral doses of GR43175 administered to healthy male volunteers. Cephalalgia 9(Suppl. 10), 414-415 (1989).
18. Bateman DN. Sumatriptan. Lancet 341, 221-224 (1993). Review article.
19. Visser WH, Ferrari MD, Bayliss EM, Ludlow S, Pilgrim AJ. Treatment of migraine attacks with sc. sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. Cephalalgia 12(5), 308-313 (1992).
20. Mathew NT, Dexter J, Couch J et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch. Neurol. 49(12), 1271-1276 (1992).
21. Mushet GR, Cady RK, Baker CC, Clements B, Gutterman DL, Davis R. Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System. Clin. Ther. 18(4), 687-699 (1996).
22. Dahlóf CGH. Characteristics of different routes of administration. In: The Diptans: Novel Drugs For Migraine. Humphrey P, Ferrari M, Olesen J (Eds). Oxford University Press, NY, USA, 80-90 (2001).
23. Cady RK, Wendt JK, Kirchner JR et al. Treatment of acute migraine with subcutaneous. sumatriptan. JAMA 265, 2831-2835 (1991).
24. Sheftell FD, Weeks RE, Rapoport AM, Siegel S, Baskin S, Arrowsmith F. migraine in a tertiary care center. Headache 34(2), 67-72 (1994).
25. Dahlof C, Putnam G, Mansbach H et al. Sumatriptan tablets are effective for migraine attacks with onset at anytime. Cephalalgia 20, 253 (2000).
26. Fox AW, Davis RL. Migraine chronobiology. Headache 38(6), 436-441(1998).
27. Winner P, Adelman J, Aurora S et al. Pain-free results of sumatriptan 6 mg sc. in the treatment of morning migraine. Results of two prospective, randomized, double-blind, placebo-controlled studies. Headache 43, 234 (2003).
28. Bousser MG, D'Allens H, Richard A. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group. J. Intern. Med. 234(2), 211-216 (1993).
29. Kaniecki RG. Mixing sumatriptan: a prospective study of stratified care using multiple formulations. Headache 41(9), 862-866 (2001).
30. Goldstein J, Ryan R, Jiang K et al. and the Rizatriptan Protocol 046 Study Group. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache 38, 737-747 (1998).
31. Oral Sumatriptan Dose-Defining Study Group. Sumatriptan - an oral dose-defining study. Eur. Neurol. 31, 300-305 (1991). Dose-defining study
32. Halpern MT, Lipton RB, Cady RK, Kwong WJ, Mario KO, Batenhorst AS. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache 42(10), 984-999 (1998).
33. Cottrell CK, Gibson JG, Waller SW, Holroyd KA, O'Donnel F. The timing of triptan use and its effect on migraine-related disability Cephalalgia 21, 339-340 (2001).
34. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 18, 532-538 (1998).
35. Cutler N, Mushet GR, Davis R, Clements Ms, Whitcher L. Oral sumatriptan for the acute treatment of migraine: evaluation of three dose strengths. Neurology 45(Suppl, 7), 5-9 (1995).
36. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 38(3), 184-190 (1998).
37. Sargent J, Kirchner JR, Davis R, Kirkhart B. Oral sumatriptan is effective and well-tolerated for the acute treatment of migraine: results of a multicenter study. Neurology 45(8 Suppl. 7), S10-S14 (1995).
38. Lipton RB, Stewart WF, Cady R et al. 2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 40(10), 783-791 (2000). Shows that sumatriptan is effective for the full range of a headache in a migraine sufferer.
39. Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 40(10), 792-797 (2002).
40. Winner P, Mannix LK, Putnam DG et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: two randomized, double-blind, placebo-controlled studies. Mayo Clin. Proc. 78(10), 1214-1222 (2003).
41. Cady RK, Sheftell F, Lipton RB et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther. 22(9), 1035-1048 (2000).
42. Nett R, Landy S, Shackelford S, Richardson MS, Ames M, Lener M. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet. Gynecol. 102(4), 835-842 (2003).
43. Hamalainen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? Neurology 48(4), 1100-1103 (1997).
44. Elser JM. Sumatriptan in the treatment of pediatric migraine. Clin. Res. 41, 729 (1993).
45. Hoerlein M, McMonigle G, Franz DN. Sumatriptan therapy of pediatric migraines. Ann. Neurol. 36, 582 (1994).
46. Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology 49(5), 1225-1230 (1997).
47. Moore KH, Hussey EK, Shaw S, Fuseau E, Duquesnoy C, Pakes GE. Safety, tolerability and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia 17(4), 541-550 (1997).
48. Salonen R, Ashford E, Dahlof C. Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group. J. Nuerol. 241, 463-469 (1994).
49. The Finnish Sumatriptan Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur. Neurol 31, 332-338 (1991).
50. Ryan P, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M. Sumatriptan nasal spray for the acute treatment of migraine: results of two clinical studies. Neurology 49, 1225-1230 (1997).
51. Ashford E, Salonen R, Saiers J, Woessner M. Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Cephalalgia 18(5), 273-277 (1998).
52. Winner P, Rothner AD, Saper J et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 106(5), 989-997 (2000).
53. Rothner AD, Winner P, Nett R et al. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. Clin. Ther. 22(12), 1533-1546 (2000).
54. Geraud G, Valette C. Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients. Rev. Neurol. 156(6-7), 646-653 (2000).
55. Carpay JA, Linssen WH, Koehler PJ, Arends LR, Tiedink HG. Efficacy of sumatriptan nasal spray in recurrent migrainous headache: an open prospective study. Headache 43(4), 395-399 (2003).
56. Bertin L, Brion N, Farkkila M, Gobel H, Wessely P. A dose-defining study of sumatriptan suppositories in the acute treatment of migraine. Int. J. Clin. Pract. 53(8), 593-508 (1999).
57. Tepper SJ, Cochran A, Hobbs S et al. Sumatriptan suppositories for the acute treatment of migraine. Int. J. Clin. Pract. 1, 31-35 (1998).
58. Gõbel H. A placebo-controlled, dose-defining study of sumatriptan suppositories in the acute treatment of migraine. Front Headache Res. 6, 203-206 (1997).
59. Henriksson A. Safety and efficacy of sumatriptan suppositories in the acute treatment of migraine attacks. Cephalalgia 15(Suppl. 14), 235 (1995)
60. Carpay H, Cruccu G, Boswell D, Kinrade F, Jones M. Efficacy of a new formulation of sumatriptan tablets when administered early in a migraine attack. Meeting platform presentation, Monte Carlo, Monaco, October 2003. Head. Care Practic. Clin. (2003).
61. Welch KM, Saiers J, Salonen R. Triptans and coronary spasm. Clin. Pharmacol. Ther. 68, 337-338 (2000).
62. Yu DK. The contributions of p-glycoprotein to pharmacokinetic drug-drug interactions. J. Clin. Pharmacol. 39, 1203-1211 (1999).
63. Ramadan NM. Acute treatment of migraine: Some blind alleys. Curr. Med. Res. Op. 17, S71-S80 (2001)
64. Ramadan NM. Acute treatment of migraine: future developments. Curr. Med. Res. Op. 17, S81-S86 (2001).
65. Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs 17(1), 1-7 (2003).